#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Search results: (10000)



News What is the significance of hormones in the pathophysiology of migraine?

Migraine is a complex neurovascular disease characterized by the dysfunction of the nociceptive trigeminovascular system in its pathophysiology. Its prevalence is 2-3 times higher in women than in men. The cause of this difference has not yet been fully elucidated, but it appears that the fluctuation of ovarian hormone levels and its influence on CGRP plays an important role. The following article summarizes findings on the hormonal influence of migraine and also discusses new prophylactic drugs –⁠ anti-CGRP antibodies.
Source: Migraine 27. 7. 2020

News Transition of Hemophilia A Patients with a History of Coagulation Factor Inhibitor to Emicizumab

During the World Federation of Hemophilia (WFH) conference, held virtually in June 2020, interesting results were presented for patients with Hemophilia A who had a history of FVIII inhibitor and are now using Emicizumab.
Source: Quality Life Even with Hemophilia 3. 8. 2020

News Major Orthopedic Procedures in Patients with Inhibitor Treated with Emicizumab

Italian authors presented the results of a study of a small series of hemophilia patients with inhibitors treated with emicizumab, who underwent major orthopedic surgery, at the World Federation of Hemophilia (WFH) forum. This information is very important, as emicizumab, being a new drug, offers new perspectives on how to ensure surgery for these highly risky patients.
Source: Quality Life Even with Hemophilia 28. 7. 2020

Články časopisu Case report of a gigantic recurrent angiomyolipoma in a horseshoe kidney

Author of the article: Markéta Hulová, Michal Staník, Daniel Macík, Jan Doležel Source: Česká urologie | 1/2020 9. 3. 2020

News An Introductory Word to the Section on Hereditary Angioedema —⁠ MUDr. Roman Hakl, Ph.D.

Hereditary angioedema (HAE) is a genetically conditioned disease, currently classified into HAE with C1 inhibitor deficiency (HAE-C1-INH), referred to as HAE-I and HAE-II, and HAE with normal level and function of C1 inhibitor (HAE nC1-INH), also referred to as HAE-III (1).
Source: Hereditary Angioedema 29. 7. 2020

News Domestic application of biological asthma treatment improves quality of life and reduces doctor visits

The benefits of the possibility of home application of omalizumab, a monoclonal antibody indicated for patients with severe allergic asthma, are summarized by Dr. Jakub Novosad, Ph.D., from the Institute of Clinical Immunology and Allergology, Charles University Medical Faculty and University Hospital Hradec Králové.
Source: Asthma under control 9. 4. 2020

News Prevalence of Diabetics Among Patients with COVID-19 and the Impact of DM on the Course of Infection

Italian authors published the results of a meta-analysis of studies at the end of March, assessing the prevalence of diabetes among individuals infected with SARS-CoV2 and the impact of diabetes on the severity and progression of the infection.
Source: Modern Treatment of Diabetes 14. 4. 2020

News American Heart Association: Side Effects of Statins Overview and Context

The American Heart Association (AHA) report provides an updated summary of knowledge on the safety of statin use. Despite warnings appearing in professional literature and general media, it assures that statins are an effective and safe modality for treating hypercholesterolemia.
Source: Cardiovascular Risks 15. 4. 2020

News Third Generation Targeted Therapy for ROS1-Positive NSCLC

The potent third-generation tyrosine kinase inhibitor, lorlatinib, has shown activity in preclinical studies against nearly all known mutations in the ALK and ROS1 genes that lead to resistance to crizotinib treatment. Moreover, lorlatinib crosses the blood-brain barrier, offering hope for patients with CNS metastases. The results of a clinical evaluation of the efficacy and safety of lorlatinib in patients with advanced ROS1-positive non-small cell lung cancer (NSCLC) were published in The Lancet Oncology.
Source: Genetic Profile and Treatment of NSCLC 15. 4. 2020

News Key Role of HRCT in Diagnosing Idiopathic Pulmonary Fibrosis

Idiopathic pulmonary fibrosis is often an unjustly overlooked disease. The truth is that it is a rare disease, but the prognosis for patients is very poor. To improve quality of life and chances of longer survival, early diagnosis is crucial, with imaging methods, specifically high-resolution computed tomography (HRCT), playing a key role.
Source: Pulmonary Fibrosis 15. 4. 2020

News Idiopathic Pulmonary Fibrosis: Rare Disease with Severe Prognosis

Idiopathic pulmonary fibrosis (IPF) represents a diagnostic and therapeutic challenge. This rare diffuse primary fibroproliferative involvement of lung tissue is characterized by progressive exertional dyspnea, with antifibrotic treatment being the first-line therapeutic modality.
Source: Pulmonary Fibrosis 14. 4. 2020

News 6 Years Follow-Up of Patients with Breast Cancer in the APHINITY Study

The primary analysis of results from the APHINITY clinical trial supported the combined anti-HER2 treatment with trastuzumab and pertuzumab in combination with chemotherapy in patients with early HER2-positive breast cancer. At the end of last year, efficacy and safety results of this treatment after more than 6 years of follow-up were presented.
Source: Breast Carcinoma 17. 4. 2020

News Idiopathic Pulmonary Fibrosis from the Perspective of an Outpatient Pulmonologist

Idiopathic pulmonary fibrosis represents a rare disease of lung tissue with an as-yet-unexplained etiology. In the framework of differential diagnosis, it is necessary to consider the disease, as early diagnosis combined with the deployment of antifibrotic therapy extends patients' lives.
Source: Pulmonary Fibrosis 16. 4. 2020

News Impact of Candesartan on Achieving Remission in Patients with Active IgA Nephropathy

IgA nephropathy is the most common glomerulonephritis worldwide and in the Czech Republic. The effect of candesartan (an angiotensin receptor blocker) on the remission of active IgA nephropathy in patients treated with steroid pulses and tonsillectomy was investigated by the randomized study presented below.
Source: Sartans in the Treatment of Hypertension 18. 4. 2020

News Impact of Lifestyle on the Benefit of Pharmacotherapy for Hypertension and Dyslipidemia

Antihypertensive and hypolipidemic therapy reduces the risk of cardiovascular (CV) diseases. Observational studies have shown that factors of a healthy lifestyle also have this influence. But is the benefit of pharmacotherapy for hypertension and dyslipidemia influenced by adherence to a healthy lifestyle? This question was attempted to be answered by an analysis of data from the clinical study HOPE-3.
Source: Sartans in the Treatment of Hypertension 18. 4. 2020

1 79 80 81 82 83 667
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#